EARLY MARKERS OF PROGRESSION OF HEART FAILURE AND APOPTOSIS: THEIR ROLE IN PREDICTING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION

Aim. To study the interrelation between hyperhomocysteinemia, the expression of endothelin-1, Fas-ligand (Fas-L), atrial natriuretic peptide (NT-proBNP) and the severity and course of chronic heart failure (CHF) in patients with coronary heart disease (CHD) during the 12-month prospective study to develop forecasting models of the probability of adverse cardiovascular events depending on gender.

Materials and methods. The study included 94 patients with CHF. The control group included 32 people who did not have cardiovascular disorders. At baseline and after 12 months of observation in the blood serum levels of sFas-L, homocysteine, endothelin-1 and NT-proBNP were measured by enzyme-linked immunosorbent solid phase assay.

Results. It is established that predictors of adverse cardiovascular events in men with coronary artery disease are elevated serum levels of homocysteine, the increased expression of NT-proBNP, platelet-derived growth factor AB (PDGF-AB) associated with the size of the left atrium and hypertriglyceridemia when in women are hyperhomocysteinemia with increased expression of NTproBNP, and TNF-α, as well as the enlarged size of the left atrium and hypercreatininemia. The most informative indicators of prognosis of cardiovascular complications in patients with CHF are homocysteinemia and the level of NT-proBNP.

Conclusion. It is established that there is the interrelation between hyperhomocysteinemia, elevated levels of endothelin-1, Fas-L and NT-proBNP in the blood serum with the severity and course of CHF in patients with coronary artery disease. Proposed individual values of the integral index of the probability of occurrence of adverse cardiovascular events for men and women that provides the innovative approach to personalize preventive treatment of these patients.

1. Eltyeb A., Graham S. Apoptosis in chronic heart failure. Cardiology, 2007, vol. 114 (3), pp. 375–379.doi:10.1016/j.ijcard.2005.11.073

2. Xiao J., She Q., Wang Y. et al. Effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction. Eur. J. of Heart Failure, 2009, vol. 11, no. 1, pp. 20–27. doi.org/10.1093/eurjhf/hfn003

3. Lockshin R.A., Zakeri Z. Caspase-independent cell deaths. Curr. Opin. Cell. Biol., 2002, vol. 14, pp. 727−733. doi. org/10.1016/s0955-0674(02)00383-6

4. Khlapov A.P., Vechersky Yu.Yu., Ryazantseva N.V., Kalyuzhin V.V., Mustafina L.R., Shipulin V.M., Novitsky V.V. Rol’ apoptoza kardiomiocitov v mehanizmah ishemicheskogo remodelirovanija miokarda [The role of cardiomyocyte apoptosis in mechanisms of ischemic myocardial remodeling] // Byulleten’ sibirskoy meditsiny − Bulletin of Siberian Medicine, 2008, vol. 7, no. 3, pp. 33−37 (in Russian).

5. Stephanou A., Scarabelli T.M., Brar B.K. et al. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J. Biol. Chem., 2001, vol. 276, pp. 28340−28347. doi. org/10.1074/jbc.m101177200

6. Adam-Klages S., Adam D., Weigmann K. et al. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphin gomyelinase. Cell, 1996, vol. 86, pp. 937−947. doi.org/10.1016/s0092-8674(00)80169-5

7. Gang L., Huhua L., Liangming W. Serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure. Clin. Med. Sci. J., 2002, vol. 17 (4), pp. 258.

8. Atasoy Р., Bozdogan O., Erekul S. et al. Fas-mediated pathway and apoptosis in normal, hyperplastic, and neoplastic endometrium. Gynecologic Oncology, 2003, vol. 91 (2), pp. 309–317. doi.org/10.1016/s0090-8258(03)00411-6

9. Soboleva E.V. Gomocisteinemija i remodelirovanie arterij u bol’nyh hronicheskimi formami IBS. Avtoref. dis. kand. med. nauk. [Homocysteinemia and remodeling of arteries in patients with chronic forms of coronary heart disease. Diss. cand. med. sci.]. Samara, 2007. 26 p. (in Russian).

10. Okubo S., Tanabe Y., Takeda K. et al. Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemiareperfusion in rabbits: role of delta-opioid receptor. Am. J. Physiol. Heart Circ. Physiol., 2004. vol. 287, pp. H1786–H1791. doi. org/10.1152/ajpheart.01143.2003

11. Teplyakov A.T., Grakova E.V., Kalyuzhin V.V., Tarasov N.I. et al. Pushnikova E.Yu., Andrianova A.V., Sinkova M.N., Isakov L.K. Novye vozmozhnosti v diagnostike dekompensirovannoj serdechnoj nedostatochnosti: klinicheskoe znachenie faktorov rosta VEGF, PDGF-AB, FGFbasic, tkanevogo ingibitora matriksnyh metalloproteinaz 1 i lipoproteinassociirovannoj fosfolipazy A2 [New opportunities for acute decompensated heart failure diagnostics and clinical value of growth factors: VEGF, PDGF-AB, FGFbasic, tissue inhibitor of metalloproteinase 1 and lipoprotein-associated phospholipase A2]. Sibirskij medicinskij zhurnal (g. Tomsk), 2015, vol. 30, no. 2, pp. 50−60 (in Russian).

12. Kalyuzhin V.V., Teplyakov A.T., Bespalova I.D., Kalyuzhina Ye.V. K voprosu ob ishemicheskoj disfunkcii miokarda [Toward the question of ischemic myocardial dysfunction]. Byulleten’ sibirskoi meditsiny − Bulletin of Siberian Medicine, 2014, vol. 13, no. 6, pp. 57−71 (in Russian).

13. Kasama S., Furuya M., Toyama T. et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. European Heart Journal, 2008,vol. 29 (12), pp. 1485−1494. doi.org/10.1093/eurheartj/ehn206

14. Denus S., Pharand C., Williamson D. Brain natriuretic peptide in the management of heart failure. Chest, 2004, vol. 125, pp. 652–668. doi.org/10.1378/chest.125.2.652

15. Bay M., Kirk V., Parner J. et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart, 2003, vol. 89, pp. 150–154. doi.org/10.1136/heart.89.2.150

16. O’Donoghue M., Chen A., Baggish A.L. et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J. Card. Fail., 2005, vol. 11 (Suppl. 5), pp. 9−14. doi. org/10.1016/j.cardfail.2005.04.011

17. Kalyuzhin V.V., Teplyakov A.T., Ryazantseva N.V., Vechersky Y.Y., Khlapov A.P., Kolesnikov R.N. Diastola serdca. Fiziologija i klinicheskaja patofiziologija [Diastole of the heart. Physiology and clinical pathophysiology]. Tomsk, TPU Publ., 2007. 212 p. (in Russian).

18. Horio T. Heart failure and circulatory peptides. Nippon Naika Gakkai Zasshi, 2005, vol. 94. pp. 201−207.

19. Karpov Yu.A. Rol’ nejrogumoral’nyh sistem v razvitii i progressirovanii hronicheskoj serdechnoj nedostatochnosti: jendotelial’nye faktory [The role of neuroendocrine systems in the development and progression of chronic heart failure: endothelial factors]. Serdechnaya nedostatochnost’, 2002, vol. 3, no. 1. pp. 22–25 (in Russian).

20. Koshkina D.E., Skvorcov A.A., Protasov V.N., Narusov O.Ju., Tereshhenko S.N. Rol’ markerov organnogo povrezhdenija u bol’nyh HSN [The role of markers of organ damage in patients with CHF]. Kardiologiia, 2014, vol. 55, no. 1, pp. 33−37 (in Russian).

21. Xiao J., She Q., Wang Y. et al. Effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction. Eur. J. of Heart Failure, 2009, vol. 11, no. 1, pp. 20–27. doi.org/10.1093/eurjhf/hfn003

22. Han H., Long H., Wang H. et al. Progressive apoptotic cell death triggered by transient oxida-tive insult in H9c2 rat ventricular cells: a novel pattern of apoptosis and the mechanisms. Am. J. Physiol. Heart Circ. Physiol., 2004, vol. 286, pp. H2169−H2182. doi.org/10.1152/ajpheart.00199.2003

23. Sabbah H.N. Apoptotic cell death in heart failure. Cardiovasc. Res., 2000. vol. 45, pp. 704−712. doi.org/10.1016/s0008-6363(99)00348-x

24. Teplyakov А.Т., Popov S.V., Kalyuzhin V.V., Garganeeva A.A., Kurlov I.O., Nilogov V.L., Rybalchenko E.V., Shilov S.N. Ocenka vlijanija karvedilola, atenolola i ih kombinacii s fozinoprilom na variabel’nost’ ritma serdca, kliniko- funkcional’nyj status i kachestvo zhizni bol’nyh s postinfarktnoj disfunkciej levogo zheludochka [Effects of carvedilol, atenolol and their combination with fosinopril on cardiac rhythm variability, clinicofunctional status and quality of life in patients with postinfarction left ventricular dysfunction]. Terapevticheskiĭ arkhiv, 2004, vol. 76, no. 9, pp. 62−65 (in Russian).

25. Tarone G., Balligand J.L., Bauersachs J., Clerk A. et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur. J. Heart Fail., 2014, vol. 16(5), pp. 494−508. doi: 10.1002/ ejhf.62.

26. Skvortsov A.A., Koshkin D.E., Protasov V.N., Narusou O.Yu., Masenko V.P., Tereshchenko S.N. Terapija pod kontrolem NT-proBNP snizhaet risk smerti i chastotu gospitalizacij u bol’-nyh posle dekompensacii serdechnoj nedostatochnosti [Therapy under the control of NT-proBNP reduces the risk of death and frequency of hospitalizations in paintion after decompensation of heart failure]. Serdechnaya nedostatochnost’, 2015, vol. 16, no, 4 (91), pp. 204−217 (in Russian).

27. Ueland T., Gullestad L., Nymo S.H., Yndestad A., Aukrust P., Askevold E.T. Inflammatory cytokines as biomarkers in heart failure. Clin. Chim. Acta., 2015, vol. 443, pp. 71−77. doi: 10.1016/j.cca.2014.09.001.

28. Protasov V.N., Skvortsov A.A., Koshkin D.E., Marusov O.Yu., Tereshchenko S.N. Ispol’zovanie sovremennyh biomarkerov v stratifikacii riska pacientov s serdechnoj ne-dostatochnost’ju [The use of modern biomarkers in the risk stratification of patients with heart failure]. Kardiologicheskij vestnik, 2014, no. 4, pp. 100−107 (in Russian).

29. de Antonio M., Lupon J., Galan A., Vila J., Urrutia A., Bayes-Genis A. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am. Heart J., 2012, vol. 163(5), pp. 821−828. doi: 10.1016/j.ahj.2012.03.004.